An extension of AC-055-310, a multi-center, open-label, single-arm, Phase 3b study of macitentan in patients with pulmonary arterial hypertension to psychometrically validate the French, Italian and Spanish versions of the PAH-SYMPACT

Trial Profile

An extension of AC-055-310, a multi-center, open-label, single-arm, Phase 3b study of macitentan in patients with pulmonary arterial hypertension to psychometrically validate the French, Italian and Spanish versions of the PAH-SYMPACT

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 28 Jul 2017

At a glance

  • Drugs Macitentan (Primary)
  • Indications Pulmonary arterial hypertension
  • Focus Adverse reactions
  • Acronyms ORCHESTRA Ext.
  • Sponsors Actelion Pharmaceuticals
  • Most Recent Events

    • 28 Jul 2017 The trial has been completed in Spain.
    • 12 Apr 2017 Planned End Date changed from 1 Mar 2017 to 31 Mar 2018.
    • 12 Apr 2017 Planned primary completion date changed from 1 Mar 2017 to 31 Mar 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top